<DOC>
	<DOCNO>NCT01293461</DOCNO>
	<brief_summary>The purpose study assess safety tolerability determine pharmacokinetics subcutaneous single multiple ( 12 ) dose administration CBX129801 ( long-acting synthetic C-peptide ) type 1 diabetes patient .</brief_summary>
	<brief_title>Safety Pharmacokinetics CBX129801 Patients With Type 1 Diabetes</brief_title>
	<detailed_description>This study conduct two part ( Part 1 Part 2 ) . Part 1 conduct three sequential dose cohort dose level escalate successive cohort . In Part 2 study , dose regimen determine pharmacokinetic data Part 1 administer 40 additional subject achieve target plasma concentration range represent commonly observed physiological C-peptide level healthy , non-diabetic individual .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>Key Give inform consent Aged 18 55 year ( Part 1 ) , Ages 18 65 year ( Part 2 ) Stable type 1 diabetes mellitus ( T1DM ) minimum 5 year Body mass index 1835 kg/m2 Be Cpeptide deficient ( assessed fasting concentration level ) Normal renal function ( assessed serum creatinine ) Be good general health ( besides T1DM ) Have abnormal sural nerve conduction velocity observe bilaterally ( Part 2 ) Key Any significant cardiovascular , hematological , renal , hepatic , pulmonary , endocrine ( except diabetes mellitus ) , central nervous , gastrointestinal condition disease Unstable glucose control Have islet cell , kidney , and/or pancreas transplant Blood loss blood donation within 56 day Drug alcohol abuse ( within 2 year ) recreational drug use ( within 3 month ) History positive test result Hepatitis B , C , and/or HIV Treatment medication peripheral neuropathy within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>